Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) will report its third-quarter 2026 financial results after U.S. markets close Wednesday, November 4, providing investors with an update as the Radnor-based …
Mineralys Sets November 4 Earnings Call as Drug Trials Advance Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat significantly reduced blood pressure and urinary protein levels in patients with chronic kidney disease, according …
Mineralys Drug Lowers Blood Pressure in Kidney Disease Trial Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat reduced a key marker of kidney damage by 52.2% compared with placebo in patients with …
Mineralys Drug Cuts Kidney Damage Marker 52% in Trial Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) has appointed two former pharmaceutical chief executives to its board of directors as the company prepares for the potential regulatory approval and …
Mineralys Adds Pharma Veterans Ahead of Potential Drug Launch Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported additional clinical evidence that its experimental hypertension drug lorundrostat can lower blood pressure in patients whose condition remains uncontrolled despite multiple …
Mineralys Drug Lowers Blood Pressure but Misses Sleep Apnea Goal Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will present Phase 3 data this month examining whether its experimental hypertension drug lorundrostat reduced both blood pressure and albuminuria in patients …
Mineralys Extends Lorundrostat Focus to Kidney Disease Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will present five studies of lorundrostat at the American Heart Association’s Hypertension Scientific Sessions this week, extending its clinical work beyond uncontrolled …
Mineralys Expands Lorundrostat Data Across Hypertension Uses Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) granted stock options and restricted stock units covering a combined 81,253 shares to two newly hired non-executive employees as part of its …
Mineralys Grants Equity Awards to New Employees Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will participate in the Stifel 2026 Virtual Cardiometabolic Forum on Sept. 30, giving investors an opportunity to hear from management as the …
Mineralys Sets Investor Forum Appearance as Lorundrostat Advances Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will present new long-term efficacy and safety data for lorundrostat in November, providing an additional clinical readout as the company advances the …
Mineralys to Present Long-Term Lorundrostat Data in November Read More